Honors of the Sixth Pharmaceutical Factory of Harbin Pharmaceutical Group

20 1 1 this year is a year in which Harbin pharmaceutical group has withstood unprecedented severe tests and strived to maintain stable economic development. Focusing on the established goals, the Group fully implemented the "six strategies", accelerated the integration of internal resources and the construction of key projects, and achieved a year-on-year increase of 7.45% in sales revenue, reaching a record high.

(A) actively promote marketing innovation, market expansion has achieved initial results.

Harbin Pharmaceutical Group regards marketing management as the top priority of all its work, and has made active exploration and bold innovation in structural adjustment, product carding and secondary development of old products. Through the implementation of marketing information project construction and the dispatch of market supervisors, a rapid response mechanism closer to the market has been established, market supervision and assessment have been strengthened, and the control ability of key links such as channels, flow direction and payment return has been further improved. Sanjing Pharmaceutical, Harbin No.6 Pharmaceutical Factory and Chinese Medicine Co., Ltd. have achieved good results by strengthening the construction of OTC team, strengthening the maintenance of terminal market, integrating the resources of primary and secondary dealers, constantly expanding terminal channels, and focusing on the sales of key incremental products. 20 1 1 year, the sales revenue of 6 1 large superior varieties produced by the group increased by 4.03% year-on-year.

(2) Accelerate the pace of scientific and technological innovation, and lay the foundation for the comprehensive integration of scientific and technological resources.

In order to continuously promote the "integrated" operation of scientific and technological innovation, Harbin Pharmaceutical Group established Harbin Pharmaceutical Group Pharmaceutical Research Institute, identified a number of key R&D products in the fields of anti-tumor, cardiovascular and biopharmaceuticals, concentrated superior resources, increased research efforts, and achieved initial results. The new product cefmetazole sodium and its preparation of Harbin Pharmaceutical Factory won the first prize of scientific and technological progress in Heilongjiang Province. 20 1 1, 17 new products, including live pig blue ear disease vaccine, obtained the production approval number. Among them, gemcitabine hydrochloride for injection, which was declared by Harbin Pharmaceutical Bio and developed by Institute of Pharmaceutical Research, is the first batch of generic anti-tumor drugs in China, which fully meets USP quality standards, indicating that the Group has made new progress in the research and development of high-quality generic drugs. Harbin Pharmaceutical Co., Ltd., Sanjing Pharmaceutical Co., Ltd., Harbin Pharmaceutical Biological Co., Ltd. and Harbin Pharmaceutical Vaccine successfully passed the accreditation review of high-tech enterprises, and Harbin Pharmaceutical Biological successfully passed the on-site inspection of the new GMP certification, becoming the first certified enterprise in the province.

(3) Actively promote asset reorganization and management integration, and improve the business quality of enterprises.

Harbin Pharmaceutical Co., Ltd. acquired all the shares of Harbin Pharmaceutical Bio and Sanjing Pharmaceutical held by Harbin Pharmaceutical Group through non-public offering of shares to Harbin Pharmaceutical Group, promoted asset restructuring and integrated medical platform resources. The restructuring plan has been approved by China Securities Regulatory Commission. This indicates that Harbin Pharmaceutical Group has fully fulfilled its share reform commitment and successfully listed the pharmaceutical assets of the group company as a whole, which greatly improved the capital operation and industry integration ability of Harbin Pharmaceutical Co., Ltd. and laid a solid foundation for Harbin Pharmaceutical Group to further implement strategic capital expansion.

The 11th Five-Year Plan period is an extraordinary five years in the development history of Harbin Pharmaceutical Group. In the face of the international financial crisis and other unfavorable factors, the Group fully implemented the innovative development strategy, realized the fundamental adjustment of the property right structure by introducing capital, turned the "bottleneck" of development into a competitive advantage, made every effort to promote the sound and rapid development of the Group's economy, and successfully completed all the tasks of the Eleventh Five-Year Plan. With great ideas, heroic spirit and generous mind, "Harbin Pharmacist" has drawn a series of gratifying and proud economic growth curves, showing the brilliant achievements and achievements of the Group's economic development.

From 2006 to 20 10, the group's main business income doubled in five years (compound annual growth rate 15%), profits and taxes increased in five years 1.2 1 times (compound annual growth rate 17.2%), and profits increased in five years. This indicates that with the joint efforts of all staff of Harbin Pharmaceutical Co., Ltd., we have successfully achieved the planned development goal of "building a new Harbin Pharmaceutical Co., Ltd." during the Eleventh Five-Year Plan period, and exceeded the strategic task of "outperforming the market with benefit indicators" issued by the board of directors of the group.

Harbin Pharmaceutical Group has significantly improved its position in the industry, and its scale strength ranks among the top 50 pharmaceutical enterprises in the world. It has been ranked among the top 100 pharmaceutical enterprises in China for five years in a row and among the top three OTC pharmaceutical manufacturers in China for five years in a row. It ranks among the top ten industries in the province for five consecutive years, and the economic scale of Harbin Pharmaceutical Group has reached more than 70% of the total economic output of the pharmaceutical industry in the province. Harbin Pharmaceutical Group has become one of the indispensable economic supports for Harbin's economic and social development.

By implementing large-scale project construction and promoting the development of emerging industries, the Group's economic operation quality and industrial energy level have reached a new level. The Group has invested 654.38+349 million yuan and implemented 3654.38+0 technical transformation projects. Up to now, * * * has completed and put into production 19 projects, with accumulated new sales revenue1500 million yuan and new profits of 300 million yuan.

Through the implementation of technological innovation, the group has obtained 60 new product approvals, and another 55 varieties are under study, of which 6 varieties are national first-class new drugs. Accumulated 89 patents authorized by the state; * * * 129 has passed the national high-tech product certification. There are 59 varieties whose annual sales income exceeds 1000 million yuan, among which the sales scale of 22 varieties exceeds 1 000 million yuan.

The influence and brand value of "Harbin Pharmaceutical" brand have hit record highs. The brand value of "Harbin Pharmaceutical" has increased from 65.438+0.0635 billion yuan in 2006 to 65.438+0.6062 billion yuan, winning the title of the most valuable brand in China pharmaceutical industry for five consecutive years and being shortlisted as one of the "Top 500 Chinese Power Brands Affecting the World"; The total evaluation value of the four well-known trademarks in China, which were selected as "Top Asian Brands 100", "Harbin Pharmaceutical", "Sanjing", "Tang Shiyi" and "Gaizhonggai", has exceeded 30 billion yuan, creating a huge intangible asset value. The Group has four international registered trademarks, such as Harbin Pharmaceutical Co., Ltd. and Tang Shiyi Co., Ltd., and the number of leading brands ranks first in the national pharmaceutical industry. Harbin Pharmaceutical Group invested 250 million yuan to support and participate in social welfare, and won the honorary titles of "Love Donation Award" and "National Excellent Enterprise with Harmonious Labor Relations" by the Ministry of Civil Affairs. In society, Harbin Pharmaceutical Group's corporate citizenship image of big enterprise, big brand, honesty and responsibility has been further established.

The past year of 2009 was the most severe year for Harbin Pharmaceutical Group since the new century. It is the year when the medical reform policy and macroeconomic fluctuations have the greatest impact and pressure on the production and operation of enterprises. It is a year of deep adjustment of enterprise management team and internal structure and the greatest degree of resource integration. It is also a year of tactical transformation, and the ability of enterprises to resist pressure and cold is the fastest.

Faced with the dual pressures of financial crisis and medical policy adjustment, we take "maintaining growth, adjusting structure, grasping projects and promoting upgrading" as the main line, turn "crisis" into "opportunity", constantly optimize the product and industrial structure, do everything possible to overcome the unfavorable factors of non-strategic capital expansion and slow growth of internal economic stock, and write brilliant chapters with courage and boldness. The group economy presents the advantages of total expansion, structural optimization, accelerated growth and quality improvement. According to incomplete statistics, in 2009, the industrial added value of group companies increased by12.16% year-on-year; Operating income increased17.95438+0% year-on-year; The profit increased by 65,438+05.05% year-on-year, of which the growth rate of operating income was 6 percentage points higher than the average growth rate of the top 25 pharmaceutical listed companies in China, and the profit growth rate was 4 percentage points ahead. Since the establishment of 1989 Harbin Pharmaceutical Group, the comprehensive economic benefits of Harbin Pharmaceutical Group have ranked first among pharmaceutical enterprises in Heilongjiang Province for 20 consecutive years. Since 2005, the profit index and brand value have ranked first among 4738 pharmaceutical enterprises in China for five consecutive years. In 2009, the brand evaluation value of Harbin Pharmaceutical Co., Ltd. reached151900,000 yuan, a year-on-year increase of 670 million yuan, ranking among the top 500 Asian brands.

Practice has proved that we should pay attention to strategic planning and tactical coordination, be broad-minded and quick-thinking, find and cultivate favorable factors from adversity, and plan ahead at the beginning of the crisis; When the crisis strikes, we should act decisively, combine maintaining growth with expanding domestic demand and restructuring, highlight the three key words of "Harbin Pharmaceutical Thought" to deal with the impact, and take the road of scientific development that adapts to the characteristics of Harbin Pharmaceutical Group, which is the key to the group's economic rise against the trend and sustained success in 2009.

First, aim at a goal, integrate superior resources and create a new pattern of industrial cluster development. On the one hand, adhere to the professional and intensive industrial development cooperation platform, actively absorb and strive for the industrial transfer of multinational pharmaceutical enterprises, and promote the upgrading of the group's pillar industries by external increments. The Group has signed a letter of intent with world-renowned multinational pharmaceutical companies to operate high-end cephalosporin varieties, and plans to establish a long-term strategic cooperative relationship to jointly promote the accelerated development of China's antibiotic industry, which has opened the prelude for Harbin Pharmaceutical Group to cooperate with world-class counterparts. Chinese medicine company successfully increased its capital and held shares in Henan Shangqiu Baichuan Pharmaceutical Co., Ltd., thus realizing the coverage of enterprise sales network in the Central Plains. Baichuan Pharmaceutical's medicinal material base will also play the role of supplying main raw materials for Chinese medicine enterprises and further expand the industrial chain of Chinese medicine. On the other hand, it is necessary to re-examine the resource endowment within the Group from the perspective of sustainable development, implement the development strategy of specialization of production and operation, proceed from the overall interests of the Group, gradually rationalize the division of labor and cooperation within the industrial chain of the Group, and become stronger and better in the core areas. The group's internal resource integration project has achieved phased results, realizing complementary advantages, resource sharing, intensive management and low-cost operation, and strengthening the industrial chain of health care products main business and direct sales sector.

The second is to seize a main line, strengthen independent innovation, and form a new bright spot of subsequent scale-dominant varieties. In view of the market opportunities and demand brought by the new medical reform policy, we will speed up the reserve and research and development of superior products with great market potential and high technical barriers, increase investment in scientific research and development, and plan to introduce a number of important technologies, products and standards with independent intellectual property rights through public bidding. * * * It covers 9 major fields and more than 60 categories, with the largest scale and quantity in the history of the Group. Under the strict requirements of national SFDA for new drug registration, the Group obtained 7 approvals for new drug production, 70 new drugs under research and 6 new drugs to be approved/kloc-0. Harbin Pharmaceutical General Factory has obtained the certificate of "National Key New Product" for Cefotian Hydrochloride raw materials and preparations; Sanjing Pharmaceutical's "New Oral Sustained-release Preparation and Technology Platform Project" and Harbin Pharmaceutical Biological Company's "Innovative Anti-tumor Drug-Recombinant Endostatin 30 Peptide Research and Development Project" were included in the "National Major New Drug Creation Project". With the powerful engine of the implementation of major scientific and technological projects of the Ministry of Science and Technology, the group's scientific and technological innovation system, new drug research and development, new product pilot test and industrialization will surely get greater development.

Third, adhere to one principle, promote excellent management, and activate new impetus to speed up and increase efficiency. Starting from the mechanism innovation, we constantly eliminated the "management shortcomings" by strengthening internal control, and made important progress in internal control construction, quality risk control, cost control, safety production management, and senior leading cadre management. In order to integrate the resources of the Group's internal procurement channels, the Group established the bidding and purchasing department, further standardized the bidding and purchasing procedures for bulk materials and media advertisements, promoted the centralized management of raw material procurement within the Group step by step, and carried out the "Shuangyou Sunshine Procurement" project in depth, saving the procurement cost by 45 1 10,000 yuan throughout the year. By strengthening the group's cash flow, comprehensive budget and centralized financial control, the functions of the four "cash pools" of the group company, Harbin Pharmaceutical Co., Ltd., Sanjing Pharmaceutical Co., Ltd. and pharmaceutical companies have been further exerted, effectively improving the ability of enterprises to control funds and the quality of operation.

The stormy year of 2009 has passed. In the "examination room" facing the financial crisis, Harbin Pharmaceutical Group is firm and calm, moving forward in the storm, standing upright in the storm, overcoming many difficulties, completing arduous tasks and handing over an excellent answer sheet.